QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 beyond-air-exercises-outstanding-common-warrants-for-gross-proceeds-of-325m-through-immediate-exercise-of-144m-warrants-at-221share-issues-720k-new-warrants-at-00625-with-5-year-term

Beyond Air, Inc.

 beyond-air-granted-orphan-designation-status-for-7-nitro-1h-indazole-for-the-treatment-of-malignant-glioma

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1091925

 d-boral-capital-maintains-buy-on-beyond-air-maintains-11-price-target

D. Boral Capital analyst Jason Kolbert maintains Beyond Air (NASDAQ:XAIR) with a Buy and maintains $11 price target.

 d-boral-capital-maintains-buy-on-beyond-air-maintains-11-price-target

D. Boral Capital analyst Jason Kolbert maintains Beyond Air (NASDAQ:XAIR) with a Buy and maintains $11 price target.

 beyond-air-affirms-fy2026-sales-guidance-of-1200m-1600m-vs-1332m-est

Beyond Air (NASDAQ:XAIR) affirms FY2026 sales outlook from $12.00 million-$16.00 million to $12.00 million-$16.00 million vs $1...

 beyond-air-q1-eps-153-misses-007-estimate-sales-176m-beat-175m-estimate

Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(0.07) ...

 beyond-air-awarded-national-group-purchasing-agreement-for-therapeutic-gases-with-premier-inc

Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharma...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION